Circulating levels of the components of the GH/IGF-1/IGFBPs axis total and intact IGF-binding proteins (IGFBP) 3 and IGFBP 4 and total IGFBP 5, as well as PAPPA, PAPPA2 and Stanniocalcin-2 levels are not altered in response to energy deprivation and/or metreleptin administration in humans

What Was Tested

This clinical trial paper looks at IGF-1 LR3.

It remains unclear whether food deprivation induces changes in components of the GH/IGF-1/IGFBPs axis and if yes, which ones are mediated by leptin, an adipocyte secreted hormone regulating neuroendocrine response to energy deprivation in animals and humans.

Who Took Part

The abstract describes 11 men taking part.

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Fasting, Food Deprivation, Glycoproteins, Growth Hormone, Hypothalamic Diseases, Insulin-Like Growth Factor I and Intercellular Signaling Peptides and Proteins.

The authors tagged it with the keywords Hypothalamic amenorrhea, IGFBPs, Leptin, PAPPA and Stanniocalcin-2.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of IGF-1 LR3 in 11 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Metabolism: clinical and experimental), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.